GENELUX CORPORATION Research and Development Expense
GENELUX CORPORATION (GNLX) reported Research and Development Expense of $6.51 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-13
- GENELUX CORPORATION research and development expense for the quarter ending 2026-06-30 was $6.51M, a 36.78% increase year-over-year.
- GENELUX CORPORATION research and development expense for the quarter ending 2026-03-31 was $5.78M, a 22.99% increase year-over-year.
- GENELUX CORPORATION research and development expense for the quarter ending 2025-12-31 was $5.65M, a 13.28% decline year-over-year.
- GENELUX CORPORATION research and development expense for the quarter ending 2025-09-30 was $4.74M, a 17.03% increase year-over-year.
- GENELUX CORPORATION research and development expense for fiscal 2025 was $19.85M, a 4.49% increase from fiscal 2024.
- GENELUX CORPORATION research and development expense for fiscal 2024 was $19.00M, a 48.81% increase from fiscal 2023.
- GENELUX CORPORATION research and development expense for fiscal 2023 was $12.77M, a 40.64% increase from fiscal 2022.
- GENELUX CORPORATION research and development expense for fiscal 2022 was $9.08M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $6.51M 10-Q · filed 2026-08-13 | $12.29M 10-Q · filed 2026-08-13 | $17.94M derived: sum of 3 quarters · filed 2026-08-13 | $22.68M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $5.78M 10-Q · filed 2026-05-07 | $11.43M derived: sum of 2 quarters · filed 2026-05-07 | $16.17M derived: sum of 3 quarters · filed 2026-05-07 | $20.93M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $5.65M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $10.39M derived: sum of 2 quarters · filed 2026-03-19 | $15.15M derived: sum of 3 quarters · filed 2026-08-13 | $19.85M 10-K · filed 2026-03-19 |
| 2025-09-30 | $4.74M 10-Q · filed 2025-11-05 | $9.50M derived: sum of 2 quarters · filed 2026-08-13 | $14.20M 10-Q · filed 2025-11-05 | $20.72M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $4.76M 10-Q · filed 2026-08-13 | $9.46M 10-Q · filed 2026-08-13 | $15.98M derived: sum of 3 quarters · filed 2026-08-13 | $20.03M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $4.70M 10-Q · filed 2026-05-07 | $11.22M derived: sum of 2 quarters · filed 2026-05-07 | $15.27M derived: sum of 3 quarters · filed 2026-05-07 | $19.69M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $6.52M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $10.57M derived: sum of 2 quarters · filed 2026-03-19 | $14.99M derived: sum of 3 quarters · filed 2026-03-19 | $19.00M 10-K · filed 2026-03-19 |
| 2024-09-30 | $4.05M 10-Q · filed 2025-11-05 | $8.47M derived: sum of 2 quarters · filed 2025-11-05 | $12.48M 10-Q · filed 2025-11-05 | $16.64M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | $4.42M 10-Q · filed 2025-08-07 | $8.43M 10-Q · filed 2025-08-07 | $12.59M derived: sum of 3 quarters · filed 2025-08-07 | $15.41M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $4.01M 10-Q · filed 2025-05-06 | $8.17M derived: sum of 2 quarters · filed 2025-05-06 | $10.99M derived: sum of 3 quarters · filed 2025-05-06 | $13.93M derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | $4.16M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $6.98M derived: sum of 2 quarters · filed 2025-03-28 | $9.92M derived: sum of 3 quarters · filed 2025-03-28 | $12.77M 10-K · filed 2025-03-28 |
| 2023-09-30 | $2.82M 10-Q · filed 2024-11-14 | $5.76M derived: sum of 2 quarters · filed 2024-11-14 | $8.61M 10-Q · filed 2024-11-14 | $11.07M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $2.94M 10-Q · filed 2024-08-14 | $5.79M 10-Q · filed 2024-08-14 | $8.26M derived: sum of 3 quarters · filed 2024-08-14 | $10.67M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $2.85M 10-Q · filed 2024-05-09 | $5.31M derived: sum of 2 quarters · filed 2024-05-09 | $7.73M derived: sum of 3 quarters · filed 2024-05-09 | $9.55M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $2.47M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $4.88M derived: sum of 2 quarters · filed 2024-03-29 | $6.71M derived: sum of 3 quarters · filed 2024-03-29 | $9.08M 10-K · filed 2024-03-29 |
| 2022-09-30 | $2.41M 10-Q · filed 2023-11-14 | $4.24M derived: sum of 2 quarters · filed 2023-11-14 | $6.61M 10-Q · filed 2023-11-14 | |
| 2022-06-30 | $1.83M 10-Q · filed 2023-08-14 | $4.20M 10-Q · filed 2023-08-14 | ||
| 2022-03-31 | $2.37M 10-Q · filed 2023-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |